Comparative evaluation of therapeutic DNA vaccines against Trypanosoma cruzi in mice

Página do item simplificado
dc.contributor.authorSanchez-Burgos, Gilma
dc.contributor.authorMezquita-Vega, R. Gabino
dc.contributor.authorEscobedo-Ortegon, Javier
dc.contributor.authorRamirez-Sierra, Maria Jesus
dc.contributor.authorArjona-Torres, Arletty
dc.contributor.authorOuaissi, Ali
dc.contributor.authorRodrigues, Mauricio Martins [UNIFESP]
dc.contributor.authorDumonteil, Eric
dc.contributor.institutionUniv Autonoma Yucatan
dc.contributor.institutionINSERM
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T13:48:53Z
dc.date.available2016-01-24T13:48:53Z
dc.date.issued2007-08-01
dc.description.abstractChagas disease, caused by the protozoan parasite Trypanosoma cruzi, is a major public health problem in most of Latin America. A key priority is the development of new treatments, due to the poor efficacy of current ones. We report here the comparative evaluation of therapeutic DNA vaccines encoding various T. cruzi antigens. ICR mice infected with 500 parasites intraperitoneally were treated at 5 and 12 days postinfection with 20 mu g of plasmid DNA encoding T. cruzi antigens TSA-1, TS, ASP-2-like, Tc52 or Tc24. Treatment with plasmid encoding TS and/or ASP-2-like antigens had no significant effect on parasitemia or survival. Treatment with Tc52 DNA significantly reduced parasitemia, as well as cardiac parasite burden, and improved survival, although myocarditis was not significantly affected. Finally, treatment with plasmids encoding Tc24 and TSA-1 induced the most complete control of disease as evidenced by significant reductions in parasitemia, mortality, myocarditis and heart parasite burden. These data demonstrate that therapeutic vaccine efficacy is dependent on the antigen and suggest that DNA vaccines encoding Tc24, TSA-1, and Tc52 represent the best candidates for further studies of a therapeutic vaccine against Chagas disease.en
dc.description.affiliationUniv Autonoma Yucatan, Parasitol Lab, Ctr Invest Reg Dr Hideyo Noguchi, Merida, Yucatan, Mexico
dc.description.affiliationINSERM, IRD, UR 008, Ctr IRD Montpellier, Montpellier, France
dc.description.affiliationUniversidade Federal de São Paulo, CINTERGEN, Dept Microbiol Inmunol & Parasitol, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, CINTERGEN, Dept Microbiol Inmunol & Parasitol, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent333-341
dc.identifierhttp://dx.doi.org/10.1111/j.1574-695X.2007.00251.x
dc.identifier.citationFems Immunology and Medical Microbiology. Malden: Wiley-Blackwell, v. 50, n. 3, p. 333-341, 2007.
dc.identifier.doi10.1111/j.1574-695X.2007.00251.x
dc.identifier.issn0928-8244
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/29886
dc.identifier.wosWOS:000247817800008
dc.language.isoeng
dc.publisherWiley-Blackwell
dc.relation.ispartofFems Immunology and Medical Microbiology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.licensehttp://olabout.wiley.com/WileyCDA/Section/id-406071.html
dc.subjectprotozoaen
dc.subjectchagas diseaseen
dc.subjecttherapeutic vaccineen
dc.subjectimmunotherapyen
dc.titleComparative evaluation of therapeutic DNA vaccines against Trypanosoma cruzi in miceen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
Em verificação - Geral